According to a recent poll conducted by the healthcare policy research group KFF, nearly half of U.S. adults have expressed their intention to receive a Covid-19 vaccine this year. This result indicates a higher demand than initially anticipated.
Although it's important to note that not everyone who claims they will get vaccinated actually follows through, the positive response from the survey is encouraging for vaccine manufacturers. Previously, both Moderna and Pfizer had revised their estimates for the number of Americans expected to be vaccinated in 2023, reducing it from 100 million.
Pfizer's Chief Financial Officer recently stated that the company now anticipates a Covid-19 vaccination rate of approximately 24% in the United States this year, which equates to around 80 million doses. Moderna, on the other hand, expects to distribute between 50 million to 100 million doses.
The KFF poll suggests that the actual uptake of vaccines may align more with the higher end of Moderna's estimates.
During the Australian winter, there was a decline in demand for vaccines, leading to a revision of vaccination projections. Additionally, there was a growing belief among investors that Americans were becoming disinterested in getting vaccinated. However, recent developments challenge this notion.
The rise in hospital admissions of Covid-19 patients during July and August has put the virus back into the public spotlight. While the increase in hospitalizations seems to be stabilizing, the initial surge in vaccine uptake has strained supply chains, resulting in some appointments being canceled.
Higher-Than-Anticipated Interest in Covid-19 Vaccines, According to KFF Poll
A recent poll conducted by the KFF reveals a significant level of interest in the new Covid-19 vaccines. Among the adults surveyed, 23% stated that they will definitely get the vaccine, while another 23% said they will probably do so. These figures suggest that approximately 110 million U.S. adults plan to receive the shots this year, ensuring a high vaccination rate across the country.
However, it is important to note that fewer individuals actually follow through with getting vaccinated compared to those who express their intention to do so in polls. Furthermore, the poll reveals concerning statistics regarding vaccination rates. Roughly a quarter of adults who have previously received a Covid-19 vaccine state that they will not be getting this new vaccine. Additionally, among those who have already been vaccinated, 37% do not plan to receive a dose this year.
Regarding children, the poll indicates that most parents do not intend to have their children vaccinated with the new shot. This prediction suggests lower uptake among children compared to adults.
Despite these considerations, the poll findings indicate a strong intention among the American public to get vaccinated, surpassing some of the more pessimistic estimates. This bodes well for Moderna's expected vaccination rate range.
It is worth mentioning that both Moderna and Pfizer have experienced declines in their stock value this year due in part to uncertainties surrounding the longevity of their Covid-19 vaccine franchises. Moreover, the federal government's decision to shift the responsibility of vaccine acquisition and distribution from themselves to the private market has contributed to the challenges faced by these companies.